-
Dr. Rumi: Analysis of Effective Intervention Methods for MAFLD and HCC
Recently, Combined GIHep&SHC 2024 was successfully held in Singapore. Experts in the field of liver disease from around the world gathered together to discuss the latest developments, challenges, and opportunities in liver disease. Reporters from Hepatology Digest rushed to the scene and conducted interviews with multiple experts. During the interview, Dr. Md Shofequnnabi Rumi, Assistant…
-
Type 2 Diabetes as a Significant Factor Increasing Mortality After Liver Transplantation
At the recently concluded American Diabetes Association (ADA) Annual Meeting, an oral presentation highlighted that liver transplant patients with type 2 diabetes (T2DM) have significantly higher postoperative mortality rates compared to those without diabetes. This finding holds substantial importance for improving liver transplant success rates and enhancing long-term survival outcomes for patients.
-
Dr. Daniel Huang Qingyao: Exploring the Challenges and Future Trends of Fatty Liver in Asia
he Combined GlHep&SHC 2024 Conference will be held in Singapore from July 25th to 28th, 2024. Dr. Daniel Huang Qingyao from the National University Hospital of Singapore gave multiple presentations at the meeting. Hepatology Digest invited Dr. Daniel Huang Qingyao to share on metabolic associated fatty liver disease (MAFLD), liver disease examination methods, and other…
-
2024 CUDA丨Dr. Hao Zeng: Optimizing Treatment Strategies for Advanced Renal Cell Carcinoma, Exploring New Possibilities for Greater Patient Benefit
In recent years, with the advancements in targeted therapy and immunotherapy, significant progress has been made in the treatment of advanced renal cell carcinoma (RCC). Several large-scale phase III clinical trials involving targeted and immunotherapy combinations have been successful, marking the beginning of a new era in first-line treatment for advanced RCC. Following the successful…
-
2024 CUDA丨Dr. Liqun Zhou: Spotlight on Innovation, Domestic Surgical Robots at the Global Forefront
From August 8th to 11th, 2024, the Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association (CUDA) was held in Xi’an. The conference, organized by the Chinese Medical Doctor Association and the Urology Physicians Branch, and hosted by Xijing Hospital of the Air Force Medical University, with support from the Urology…
-
2024 CUDA | Dr. Jianming Guo: Addressing Clinical Needs of Prostate Cancer in China – Exploring Treatment Prospects from Diagnosis to Surgery
From August 8-11, 2024, the Annual Meeting of the Chinese Urological Association (CUDA) was held in Xi’an, hosted by the Chinese Medical Doctor Association and its Urological Physician Branch, organized by Xijing Hospital of the Air Force Medical University, and co-hosted by the Urology Physician Branch of the Shaanxi Medical Doctor Association. Under the theme…
-
International Lung Cancer Conference | Dr. Wentao Fang: Neoadjuvant Therapy for Locally Advanced NSCLC
Treating locally advanced lung cancer is a significant clinical challenge, with perioperative treatment being key to improving patient outcomes. At the 2024 International Lung Cancer Conference (CLC 2024), Dr. Wentao Fang from Shanghai Chest Hospital delivered a presentation titled “Neoadjuvant Therapy for Locally Advanced NSCLC.” This article provides a brief overview of his report.
-
2024 CUDA | Dr. Tao Xu: Addressing the Challenges of Prostate Cancer Androgen Deprivation Therapy, Optimal Treatment Strategies, and Future Directions
Androgen deprivation therapy (ADT), also known as castration therapy, involves lowering male hormone levels through surgery or medication to treat prostate cancer. Recently, the 2024 Annual Meeting of the Chinese Urological Association (CUDA) was successfully held in Xi’an. Following the event, Urology Frontier invited Dr. Tao Xu, Director of Urology at Peking University People’s Hospital,…
Connecting Medical Expertise through Media